Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infigratinib in FGFR-Altered Head and Neck Squamous Cell Carcinoma
NCT02706691Phase 2Terminated
- Sponsor
- University of Chicago
- Start
- Jun 2018
- Primary completion
- Feb 2019
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of infigratinib in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Chicago. Primary endpoint: Objective Response Rate at 5 years. Started Jun 2018; status: terminated.
02
Drugs
infigratinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02706691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02706691.